Phase 3 Migraine Trial, Recruiting NCT06810505 Sponsor: AbbVie Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT06810505
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with chronic migraine (with or without aura) for at least 6 months before your first visit to the trial site.
  • During the 28-day screening period before joining, you filled in a daily digital diary on at least 20 out of 28 days.
  • During that same 28-day period, you had 15 or more days with a headache.
  • During that same 28-day period, you had 8 or more days where the headache was a migraine.

Who may not be able to join:

  • You have high blood pressure that your doctor considers to be a significant medical concern.
  • You have a history of a serious condition affecting the blood, hormones, lungs, kidneys, liver, digestive system, heart, or nervous system.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
13 February 2025
Est. completion
1 March 2031

Where this trial is recruiting

🇨🇦 Canada 🇩🇰 Denmark 🇭🇺 Hungary 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal Puerto Rico 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of Participants Experiencing Adverse Events (AEs); Change From Baseline in Mean Monthly Migraine Days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov